Business
Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAkebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that nine abstracts, including several associated with vadadustat and Auryxia® (ferric citrate), have been accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting. ASN Kidney Week 2019 will take place in Washington, D.C. from November 5 to November 10, 2019 at the Walter E. Washington Convention Center. Conference attendees can meet with Company representatives at Booth #2307 to discuss Akebia’s presentations.\n\n\nFour posters and presentations are associated with vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in global Phase 3 development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis dependent (DD)-CKD patients and non-dialysis dependent (NDD)-CKD patients. All abstracts selected for presentation are summarized below and are available from ASN on the Kidney Week abstracts archive: https://www.asn-online.org/education/kidneyweek/archives/.\n\n\nVadadustat Oral and Poster Presentations: \n\n\n\n“Effect of Moderate Hepatic Impairment on Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)” (Poster TH-PO369) to be presented on November 7 from 10:00 AM to 12:00 PM ET.\n\n\n\n\n“Randomized, Double-Blinded, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat in Chronic Kidney Disease Patients with Anemia on Hemodialysis in Japan” (Oral TH-OR024) to be presented by Mitsubishi Tanabe Pharma Corporation (MTPC), Akebia’s development and commercialization collaboration partner in Japan for vadadustat on November 7 in Room #150 from 4:30 PM to 6:30 PM ET.\n\n\n\n\n“Randomized, Open-Label, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat for Treating Anemia in Non-Dialysis-Dependent CKD Patients in Japan” (Poster SA-PO229) to be presented by MTPC on November 9 from 10:00 AM to 12:00 PM ET. \n\n\n\n\n“Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia” (Oral SA-OR037) to...